Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (1125)	8/31/2003 3:44:22 AM
From: scaram(o)uche	Respond to of 1833

>> BTW, Rick- did Ms. Paige ever say whether there are any royalties involved in addition to the cash payments of the major pharma? << I didn't ask, sorry. I've always assumed that, since there was no mention of royalty, there was none. Dumb of me not to have taken the op. Maybe we can compile a list of questions that might be addressed in the next 10-K? A few gritty items. Solvay..... if you assume that SLV320 is from OSIP..... I'm using about $0.50/share. CHF is a chronic condition for many patients. It's a big market need. A good drug could run to big bucks. But, let's say 2% of 400M........ that would be nice chunk of annual change for a company with almost no burn and a cap of $19M. If you use 4% and, say, $1B? Flying blind. That is what was so nice about Axiom. Everything, if it had unfolded, would have been so visible. It had a handle on it. Pharmas will screw you if they can, and communication isn't on their agenda. It's just too preliminary to say. I'd love to see OSIP acknowledge that the asthma program ever existed. >> Put differently, what are the price targets of readers of this thread? << Mine came way down when Axiom went SQNMing. But I've now raised it to 2.50. If SLV320 is from OSIP and if it goes to phase II? I'll start looking at it like a biotech again, instead of a "value stock". But I never mind safety, and good news could come even from old partnerships. United States Patent Application 20030139427 Kind Code A1 Castelhano, Arlindo L. ; et al. July 24, 2003 -------------------------------------------------------------------------------- Bicyclic pyrimidinyl derivatives and methods of use thereof Abstract This invention pertains to compounds which specifically bind to the adenosine A1, A2a, and A3 receptors and the use of these compounds to treat a disease associated with the A1, A2a, and A3 adenosine receptors in a subject, comprising administering to the subject a therapeutically effective amount of the compounds. -------------------------------------------------------------------------------- Inventors: Castelhano, Arlindo L.; (New City, NY) ; McKibben, Bryan; (White Plains, NY) Correspondence Name and Address: John P. White Cooper & Dunham LLP 1185 Avenue of the Americas New York NY 10036 US Assignee Name and Adress: OSI Pharmaceuticals Inc. Serial No.: 227378 Series Code: 10 Filed: August 23, 2002

To: Tomato who wrote (1125)	8/31/2003 4:02:30 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

>> new insights nudged << >> what would the biotech components add << On a few occasions, I've indicated that I pray that Cadus Technologies can be spun out to current shareholders if Icahn, Paige et al. decide to go with a non-biotech flier. You want nudged insights............ The Cadus patent portfolio is, IMO, a valuable platform around which a great little company could be built. Woler didn't get the attention for the program that it deserves. Glass couldn't, given his resources and focus. Paige is trying to find someone with licensing experience to consult for her, but it's obviously going slowly. We know about Solvay, and there's reason to be enthusiastic about SLV320, IMO. We know about the "major pharmaceutical company", minus the unanswered issue that you pointed at. We do NOT know if there is continuing work at Glaxo (SmithKline) or BMY that could prove to be exciting. I believe that I'm the single individual on Earth that holds out promise. Look at it this way...... the Cadus portfolio was built around U.S. 5,482,835, King et al. from Duke. There are 10-13 years left on that patent, and it is cited in about a zillion issued patents and patent applications. patft.uspto.gov (94 references, issued U.S. patents) appft.uspto.gov:8080/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=5%2C482%2C835&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01 (63 references, published U.S. applications.... there are certainly many others out there which have not been published) Add to that my "feeling" that some newer KDUS claims will restrict many future claims, and I believe that money spent now on licensing efforts will pay big-time in the future. It is EXTREMELY important that KDUS devise a method to be vigilant. OTOH, you'd think that the ex-employees would be buying hand over fist if my enthusiasm were well-founded. If I'm correct, KDUS' leverage is still enormous. But it isn't going to materialize without threat and active protection of claims. That is, we need Icahn/Paige to play the Sibia game. :-)